INTRODUCTION: P21-activated kinase 4 (PAK), a subfamily of serine/threonine kinases originally known as a regulator of cytoskeletal dynamics and cell motility, has recently been revealed to play a key role in oncogenic signaling pathways. We studied the frequency and clinical features of PAK4-overexpressed metastatic gastric cancer. PATIENTS AND METHODS: PAK4 overexpression was screened by Western blot in 18 human gastric cancer cell lines. Immunohistochemical staining of PAK4 protein was performed in tumor specimens of 49 metastatic gastric cancer patients who received palliative capecitabine/cisplatin as first-line treatment. RESULTS: PAK4 protein overexpression was detected strongly in five gastric cell lines (AGS, MGK-28, MKN-74, SNU-216, SNU-601) and weakly in four cell lines (KATOIII, MKN-1, SNU-620, and SNU-719). PAK4 knockdown by small interfering RNA induced apoptosis in PAK4-overexpressed AGS gastric cancer cells. Immunohistochemical staining revealed PAK4 overexpressions in 4 (8.1%) of 49 metastatic gastric cancer specimens. None of the four patients with PAK4(+) responded to capecitabine/cisplatin chemotherapy, and PAK4(+) gastric cancer patients had a trend of poorer survival compared with PAK(-)(P = .876). CONCLUSIONS: We demonstrated PAK4 overexpression in a subset of gastric cancer patients, implicating a role in gastric cancer tumorigenesis. Its prognostic significance and efficacy as a drug target should be further studied.
INTRODUCTION: P21-activated kinase 4 (PAK), a subfamily of serine/threonine kinases originally known as a regulator of cytoskeletal dynamics and cell motility, has recently been revealed to play a key role in oncogenic signaling pathways. We studied the frequency and clinical features of PAK4-overexpressed metastatic gastric cancer. PATIENTS AND METHODS: PAK4 overexpression was screened by Western blot in 18 humangastric cancer cell lines. Immunohistochemical staining of PAK4 protein was performed in tumor specimens of 49 metastatic gastric cancerpatients who received palliative capecitabine/cisplatin as first-line treatment. RESULTS:PAK4 protein overexpression was detected strongly in five gastric cell lines (AGS, MGK-28, MKN-74, SNU-216, SNU-601) and weakly in four cell lines (KATOIII, MKN-1, SNU-620, and SNU-719). PAK4 knockdown by small interfering RNA induced apoptosis in PAK4-overexpressed AGS gastric cancer cells. Immunohistochemical staining revealed PAK4 overexpressions in 4 (8.1%) of 49 metastatic gastric cancer specimens. None of the four patients with PAK4(+) responded to capecitabine/cisplatin chemotherapy, and PAK4(+) gastric cancerpatients had a trend of poorer survival compared with PAK(-)(P = .876). CONCLUSIONS: We demonstrated PAK4 overexpression in a subset of gastric cancerpatients, implicating a role in gastric cancer tumorigenesis. Its prognostic significance and efficacy as a drug target should be further studied.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Marinella G Callow; Felix Clairvoyant; Shirley Zhu; Brian Schryver; David B Whyte; James R Bischoff; Bahija Jallal; Tod Smeal Journal: J Biol Chem Date: 2001-10-19 Impact factor: 5.157
Authors: Sean W Deacon; Alexander Beeser; Jami A Fukui; Ulrike E E Rennefahrt; Cynthia Myers; Jonathan Chernoff; Jeffrey R Peterson Journal: Chem Biol Date: 2008-04
Authors: Brion W Murray; Chuangxing Guo; Joseph Piraino; John K Westwick; Cathy Zhang; Jane Lamerdin; Eleanor Dagostino; Daniel Knighton; Cho-Ming Loi; Michael Zager; Eugenia Kraynov; Ian Popoff; James G Christensen; Ricardo Martinez; Susan E Kephart; Joseph Marakovits; Shannon Karlicek; Simon Bergqvist; Tod Smeal Journal: Proc Natl Acad Sci U S A Date: 2010-05-03 Impact factor: 11.205
Authors: J Lee; T Lim; J E Uhm; K W Park; S H Park; S C Lee; J O Park; Y S Park; H Y Lim; T S Sohn; J H Noh; J S Heo; C K Park; S Kim; W K Kang Journal: Ann Oncol Date: 2007-02-13 Impact factor: 32.976
Authors: Yingying Liu; Hang Xiao; Yanmei Tian; Tanya Nekrasova; Xingpei Hao; Hong Jin Lee; Nanjoo Suh; Chung S Yang; Audrey Minden Journal: Mol Cancer Res Date: 2008-07 Impact factor: 5.852
Authors: Austin L Brown; Kayla L Foster; Philip J Lupo; Erin C Peckham-Gregory; Jeffrey C Murray; M Fatih Okcu; Ching C Lau; Surya P Rednam; Murali Chintagumpala; Michael E Scheurer Journal: Neuro Oncol Date: 2017-10-01 Impact factor: 12.300